Epic targets outpatient visits with new AI tool
Ochsner Health in Louisiana is the first to go live with Epic’s new outpatient office visit tool, which leans on Epic’s artificial intelligence capabilities to pull insights from patient records.
Uncategorized
‘Ultimately it’s going to be a great financial decision’: UHS CEO speaks on Talkspace bet
The health system closed its $835 million acquisition of the virtual therapy provider on Monday. Healthcare Dive caught up with Marc Miller to discuss the rationale behind the deal.
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal Read More »
11 companies hiring in New Jersey
Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.
5 questions on Abbott’s glucose-ketone sensors
As Abbott prepares to launch its first dual-analyte sensor, endocrinologists talked to MedTech Dive about considerations for continuous ketone monitoring.
Trump picks White House aide Heidi Overton as FDA chief: reports
If Heidi Overton clears the Senate nomination process, analysts say she will have a tough job ahead to “restore predictability” to an agency battered by layoffs and controversial policies.
Trump picks White House aide Heidi Overton as FDA chief: reports Read More »
Enveda’s exercise-simulating obesity tablet clears early clinical test
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
Enveda’s exercise-simulating obesity tablet clears early clinical test Read More »
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more Read More »
Cómo saben las células madre en qué convertirse según su posición en el embrión
En las primeras horas tras la fecundación, un embrión es poco más que una esfera compacta de células idénticas. Todas poseen exactamente el mismo ADN y el mismo potencial para formar cualquier parte del cuerpo. Sin embargo, en cuestión de días, unas f …
Cómo saben las células madre en qué convertirse según su posición en el embrión Read More »
Barreras biológicas del xenotrasplante
La posibilidad de trasplantar órganos de animales a seres humanos —lo que en medicina se conoce como xenotrasplante— ya no forma parte de la ciencia ficción. En los últimos años, intervenciones quirúrgicas pioneras con corazones y riñones porcino …